Publications by authors named "Vera Chrebtow"
Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model.
Appl Health Econ Health Policy
December 2018
Background: US FDA draft guidance includes pathogen reduction (PR) or secondary rapid bacterial testing (RT) in its recommendations for mitigating risk of platelet component (PC) bacterial contamination. An interactive budget impact model was created for hospitals to use when considering these technologies.
Methods: A Microsoft Excel model was built and populated with base-case costs and probabilities identified through literature search and a survey of US hospital transfusion service directors.
Article Synopsis
- Pathogen inactivation (PI) is a method aimed at enhancing blood safety, but may lead to extra costs; this study investigates ways to eliminate certain expenses associated with current testing and procedures.
- Data were gathered from five institutions to assess potential cost savings from reduced testing requirements, decreased transfusion reactions, and improved inventory management, estimating a total potential savings of $141.65 per platelet unit.
- Although adopting PI will incur new costs, particularly with licensing for 7-day storage, it could also result in significant cost reductions and additional benefits such as expanded donor retention and scheduling flexibility.
Background: The effort to eliminate transfusion complications associated with WBCs has led to the widespread use of filters able to reduce WBC concentrations to